查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1649513

藥物釋放型支架市場：預測（2025-2030 年）

Drug Eluting Stent Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

藥物釋放型支架市場預計將從 2025 年的 114.99 億美元成長到 2030 年的 170.49 億美元，預測期內的複合年成長率為 8.20%。

藥物釋放型支架是一種由金屬製成的半剛性管狀裝置，其中裝有藥物，可緩慢釋放藥物以防止狹窄或動脈阻塞復發。支架設計和輸送技術的最新創新有望顯著降低即使在複雜病變中也會出現血管再阻塞率，從而降低早期和晚期血栓症的發生率。全球老年人口的增加是藥物釋放型支架市場的主要動力。隨著年齡的成長，人們更容易患上血管疾病，從而增加了對藥物釋放型支架等有效治療選擇的需求。此外，久坐的生活方式和不良的飲食習慣也導致動脈粥狀硬化病例的增加，其特徵是動脈中斑塊的堆積。

藥物釋放型支架市場促進因素

  • 技術進步：從標準血管成形術到藥物釋放型支架 (DES) 的轉變代表了治療方案的重大進步。透過將藥物治療直接納入支架，這種微創方法提供了許多好處，包括對血管的壓力更小、恢復時間更快、併發症風險更低。例如，Orsiro Mission 代表了將藥物直接輸送到目標動脈的技術突破，從而改善了患者的治療效果。隨著醫療專業人員尋求更有效、更少侵入性的動脈疾病治療方法，此類創新解決方案的成功實施可能會促進市場發展。

地理視角

  • 北美預計領先：預計預測期內北美將佔據藥物釋放型支架市場的大部分佔有率。這一成長歸因於優惠的報銷政策和該地區動脈相關疾病發病率的上升。此外，藥物釋放型支架技術的進步和強大的醫療保健基礎設施也促進了市場的擴張。根據《美國心臟病學會雜誌》 2023 年 2 月發表的一篇文章，對於 10 年預測風險較高的人群，美國粥狀硬化性心血管疾病的發生率為每 1,000 人年 2.60 例。這項統計數據凸顯了對藥物釋放型支架等有效治療方案的需求日益成長。

隨著老化人口增加，罹患冠狀動脈疾病 (CAD) 等心血管疾病的可能性也隨之增加，老年患者對藥物釋放型支架的需求也隨之增加。研究表明，CAD 影響約 50% 的老年女性和 70% 至 80% 的老年男性。總體而言，技術創新不斷提升和心血管疾病發病率不斷上升等因素預計將推動藥物釋放型支架市場的成長，尤其是在北美。

為什麼要購買這份報告？

  • 深刻的分析：涵蓋主要地區和新興地區，您可以獲得對客戶細分、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔的深入市場洞察。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中開闢新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問公司、中小企業和大型企業都有益且具有成本效益。

它有什麼用途？

產業與市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

  • 2022 年至 2030 年的實際資料和預測
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭定位、策略與市場佔有率分析
  • 各地區（包括細分市場和國家）的收益成長和預測分析
  • 公司概況（策略、產品、財務、主要發展等）

目錄

第 1 章 簡介

  • 市場概況
  • 市場定義
  • 研究範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 研究過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第 5 章藥物釋放型支架市場（依塗層類型）

  • 介紹
  • 聚合物基塗料
  • 無聚合物塗料

第6章藥物釋放型支架市場（依應用）

  • 介紹
  • 冠狀動脈疾病 (CAD)
  • 周邊動脈疾病(PAD)

第 7 章藥物釋放型支架市場（以最終用戶分類）

  • 介紹
  • 醫院
  • 門診手術中心
  • 其他

第 8 章藥物釋放型支架市場（按區域）

  • 介紹
  • 北美洲
    • 按塗層類型
    • 按應用
    • 按最終用戶
    • 按國家
  • 南美洲
    • 按塗層類型
    • 按應用
    • 按最終用戶
    • 按國家
  • 歐洲
    • 按塗層類型
    • 按應用
    • 按最終用戶
    • 按國家
  • 中東和非洲
    • 按塗層類型
    • 按應用
    • 按最終用戶
    • 按國家
  • 亞太地區
    • 按塗層類型
    • 按應用
    • 按最終用戶
    • 按國家

第9章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭儀錶板

第10章 公司簡介

  • Abbott Cardiovascular
  • Boston Scientific Corporation
  • Medtronic Plc
  • Biotronik
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • Biosensors International
  • Alvimedica
  • Lepu Medical Technology
  • MedicalExpo
  • Cook Medical
  • B. Braun
  • Biotronik
  • MicroPort Scientific Corporation
  • Sahajanand Medical Technologies
簡介目錄
Product Code: KSI061617277

The Drug eluting stent market is projected to grow at a CAGR of 8.20% over the forecast period, increasing from US$11.499 billion in 2025 to US$17.049 billion by 2030.

A drug-eluting stent is a metallic, semi-rigid tubular device that has a drug attached to it, allowing for a slow release of medication to prevent the recurrence of stenosis or arterial obstruction. Recent innovations in stent designs and delivery technologies are expected to significantly reduce the restenosis rate, even in complex lesions, thereby decreasing the incidence of both early and late thrombosis. The growing geriatric population worldwide is a major driver for the drug-eluting stent market, as the likelihood of developing vascular diseases increases with age, leading to greater demand for effective treatment options like drug-eluting stents. Additionally, sedentary lifestyles and poor dietary habits are contributing to a rise in cases of atherosclerosis, characterized by plaque buildup in the arteries.

Drivers of the Drug-Eluting Stent Market

  • Technological Advancements: The transition from standard angioplasty to drug-eluting stents (DES) represents a significant advancement in treatment options. By integrating medication therapy directly onto the stent, this minimally invasive approach offers numerous benefits, including reduced stress on blood vessels, faster recovery times, and lower complication risks. For example, the Orsiro Mission represents a technological breakthrough that delivers drugs directly into target arteries, thereby improving patient outcomes. The successful implementation of such innovative solutions is likely to increase market activity as healthcare professionals seek more effective and less invasive treatments for arterial disorders.

Geographical Outlook

  • North America Expected to Lead: North America is projected to hold a substantial share of the drug-eluting stent market during the forecast period. This growth can be attributed to favorable reimbursement policies and a rising incidence of artery-related diseases in the region. Furthermore, advancements in drug-eluting stent technology and a robust healthcare infrastructure have contributed to market expansion. According to the Journal of the American College of Cardiology published in February 2023, the incidence rate of atherosclerotic cardiovascular disease in the United States was 2.60 per 1,000 person-years among individuals with high 10-year predicted risk. This statistic underscores the growing need for effective treatment options like drug-eluting stents.

As the aging population is more susceptible to cardiovascular diseases such as coronary artery disease (CAD), there is an increasing demand for drug-eluting stents among older patients. Studies indicate that CAD affects approximately 50% of older women and 70%-80% of older men. Additionally, Canada's elderly population is projected to grow significantly over the next two decades, further driving demand for these medical devices.In summary, factors such as rising technological innovations and an increasing prevalence of cardiovascular diseases are expected to propel growth in the drug-eluting stent market, particularly in North America.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Drug eluting stent market is segmented and analyzed as follows:

By Coating Type

  • Polymer-Based Coating
  • Polymer-Free Coating.

By Application

  • Coronary Artery Disease (CAD)
  • Peripheral Artery Disease (PAD)

By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Others
  • Middle East and Africa
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. DRUG ELUTING STENT MARKET BY COATING TYPE

  • 5.1. Introduction
  • 5.2. Polymer-Based Coating
  • 5.3. Polymer-Free Coating

6. DRUG ELUTING STENT MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Coronary Artery Disease (CAD
  • 6.3. Peripheral Artery Disease (PAD)

7. DRUG ELUTING STENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Ambulatory Surgical Centers
  • 7.4. Others

8. DRUG ELUTING STENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Coating Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Coating Type
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Coating Type
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. UK
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Coating Type
    • 8.5.2. By Application
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. UAE
      • 8.5.4.2. Israel
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Coating Type
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. South Korea
      • 8.6.4.4. India
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Taiwan
      • 8.6.4.7. Thailand
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Abbott Cardiovascular
  • 10.2. Boston Scientific Corporation
  • 10.3. Medtronic Plc
  • 10.4. Biotronik
  • 10.5. Terumo Corporation
  • 10.6. MicroPort Scientific Corporation
  • 10.7. Biosensors International
  • 10.8. Alvimedica
  • 10.9. Lepu Medical Technology
  • 10.10. MedicalExpo
  • 10.11. Cook Medical
  • 10.12. B. Braun
  • 10.13. Biotronik
  • 10.14. MicroPort Scientific Corporation
  • 10.15. Sahajanand Medical Technologies